Related Experiment Video
Updated: Jun 23, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
Published on: August 26, 2025
Pfeiffer syndrome: a treatment evaluation
Jeffrey A Fearon1, Jennifer Rhodes
1Dallas, Texas; and Richmond, Va. From the Craniofacial Center, Medical City Children's Hospital, and the Division of Plastic and Reconstructive Surgery, Virginia Commonwealth University Medical Center, Virginia Commonwealth University Health System.
Insights
Pfeiffer syndrome management has improved, with lower mortality rates for types II and III. Aggressive airway management and early screening for Chiari malformations can further reduce risks.
Area of Science:
- Craniofacial Surgery
- Pediatric Genetics
- Neurosurgery
Background:
- Pfeiffer syndrome is a rare craniosynostosis disorder with high mortality in severe subtypes.
- Previous reports indicate mortality rates ranging from 25 to 85 percent.
- This study aimed to improve outcomes by reviewing surgically treated patients.
Purpose of the Study:
- To assess outcomes in surgically treated Pfeiffer syndrome patients.
- To identify factors contributing to improved survival and reduced complications.
- To compare outcomes across different Pfeiffer syndrome subtypes.
Main Methods:
- A 17-year retrospective outcome assessment was conducted at a single center.
- Data from surgically treated children with Pfeiffer syndrome were analyzed.
- Descriptive statistics were used to summarize patient data and treatment outcomes.
Main Results:
- Of 802 craniosynostosis patients, 28 had Pfeiffer syndrome (17 type I, 7 type II, 4 type III).
- The overall mortality rate was 7%, significantly lower than previously reported for types II and III.
- Common complications included external auditory canal atresia (59%), visual disturbances (29%), acquired Chiari malformations (84%), and hydrocephalus (61%).
Conclusions:
- The study achieved lower mortality rates for Pfeiffer syndrome types II and III compared to existing literature.
- Preemptive tarsorrhaphy is recommended to prevent visual loss.
- Aggressive airway management (early tracheostomies) and enhanced screening for Chiari malformations are crucial for further mortality reduction.
Background:
Pfeiffer syndrome is rarely encountered, even at major craniofacial centers. Published reports indicate high mortality rates (25 to 85 percent) for severely affected subtypes. The authors reviewed their surgically treated patients to improve outcomes.
Methods:
The authors conducted a 17-year, single-center, retrospective outcome assessment of all children treated for Pfeiffer syndrome, with data summarized using descriptive statistics.
Results:
Of 802 patients treated for craniosynostosis, 28 were identified with Pfeiffer syndrome: 17 were classified as type I (61 percent), seven were classified as type II (25 percent), and four were classified as type III (14 percent). The mean age was 10 years (range, 12 months to 39 years), with an average of 9.3 operations per child (2.5 cranial vaults, 1.1 Le Fort III procedures). Fifty-nine percent had external auditory canal atresia (100 percent of type III patients), and 29 percent had some visual disturbance. Tracheostomies were recommended in 100 percent of type II and III patients, and two type II patients required tracheal stenosis repairs. Eighty-four percent had acquired Chiari malformations (100 percent of type II and III patients), and 61 percent required treatment for hydrocephalus. Fifty percent of shunted patients (mean age, 7 years) have required Chiari decompressions, but no patients undergoing endoscopic third ventriculostomies (mean age, <3 years) have required treatment. The mortality rate was 7 percent, with both deaths occurring at home without proximity to surgery.
Conclusions:
The authors' mortality rates for type II and III Pfeiffer syndrome are lower than those previously published. The authors believe a preemptory tarsorrhaphy strategy can prevent visual loss and that further reductions in mortality rates are possible with aggressive airway management (early tracheostomies) and more frequent screening (e.g., magnetic resonance imaging, sleep studies) for Chiari malformations.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Psychosis: Goals of Pharmacotherapy
Nephrotic Syndrome II : Assessment and Medical Management
